IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug shows promise for kidney disease in early trial
Disease control Not yet recruitingThis study tests a new drug called FXS6837 in people with IgA nephropathy, a kidney disease. About 60 adults will receive either the drug or a placebo to see if it reduces protein in the urine, a sign of kidney damage. The goal is to find a safe and effective treatment to control…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New pill aims to slow kidney damage in IgA disease
Disease control Not yet recruitingThis study tests a new drug called HS-10542 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 90 adults will receive either the drug or a placebo to see if it safely reduces protein in the urine, a sign of kidney damage. The goal is to contr…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC